Three cases of herpes zoster radiculitis in MS patients treated with natalizumab
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier B.V.
Abstract
Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections. In addition to progressive multifocal leukoencephelopathy, other opportunistic infections have been rarely reported during Natalizumab treatment. We believe that clinicians need heightened awareness of these infections in view of the risks of serious complications.
Description
Keywords
Female, Herpes zoster/complications, Humans, Immunologic factors/adverse effects/therapeutic use, Middle aged, Multiple sclerosis, relapsing-remitting/complications/drug therapy, Natalizumab/adverse effects/therapeutic use, Young adult, Herpes zoster, Lebanon, Middle east, Multiple sclerosis, Natalizumab